At a White House event Thursday, President Trump announced deals with drugmakers Novo Nordisk and Eli Lilly to offer their popular GLP-1 obesity and diabetes drugs at lower prices for some Americans, namely some on Medicare and Medicaid plans. But questions linger about the significance of the deal.

According to the announcement, Medicare and state Medicaid programs will be able to purchase a month’s supply of Ozempic, Wegovy, Mounjaro, and Zepbound at $245 each for eligible patients. Eligible people on Medicare will have a $50 co-pay.

The negotiated price is a significant cut from the drugs’ list prices: The list price for Ozempic is $997, Wegovy is $1,350, Mounjaro is $1,080, and Zepbound is $1,086. But, of course, purchasers rarely pay drug list prices. It’s unclear how much Medicare and Medicaid would have paid for the drugs without this deal and what the savings will be.

Read full article

Comments

Origianl Creator:
Beth Mole

Original Link: https://arstechnica.com/health/2025/11/questions-swirl-after-trumps-glp-1-pricing-deal-announcement/
Originally Posted: Fri, 07 Nov 2025 18:18:07 +0000